SCHEMBL3449393

SCHEMBL3449393

CCOC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2cc(Cl)cn2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.44
ERBB2 P04626 1/20 0.44
FGFR1 P11362 2/20 0.41
P2RY12 Q9H244 3/20 0.41
PAK1 Q13153 1/20 0.40
STK17A Q9UEE5 2/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
SYK P43405 1/20 0.38
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
AXL P30530 1/20 0.37
CSNK2A1 P68400 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3447871 0.93 EGFR (0.41) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3449217 0.91 FGFR1 (0.40) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3448212 0.91 EGFR (0.41) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3448523 0.89 P2RY12 (0.43) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3450058 0.88 XDH (0.42) EGFRSTK17AJAK2CSNK2A1STK17B
SCHEMBL3447788 0.88 P2RY12 (0.41) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3435889 0.87 FGFR1 (0.44) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3450513 0.87 RXFP1 (0.41) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3448621 0.86 P2RY12 (0.48) EGFRERBB2FGFR1P2RY12PAK1
SCHEMBL3449488 0.86 P2RY12 (0.48) EGFRERBB2FGFR1P2RY12PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD EGFR 2771/4885ERBB2 2537/4885FGFR1 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.